Lauren Hartle
Private-Equity-Analyst bei Prime Impact Fund
Profil
Lauren Hartle is currently an Associate at Prime Impact Fund since 2020.
Previously, she worked as a Development Technician at AlphaVax, Inc. from 2008 to 2009.
Dr. Hartle holds a doctorate degree from Harvard University and an undergraduate degree from the University of North Carolina System, which she received in 2007.
Aktive Positionen von Lauren Hartle
| Unternehmen | Position | Beginn |
|---|---|---|
Prime Impact Fund
 Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Private-Equity-Analyst | 01.06.2020 |
Ehemalige bekannte Positionen von Lauren Hartle
| Unternehmen | Position | Ende |
|---|---|---|
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01.06.2009 |
Ausbildung von Lauren Hartle
| Harvard University | Doctorate Degree |
| University of North Carolina System | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Prime Impact Fund
Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
